Ovidrel, Ovitrelle(choriogonadotropin alfa)
Ovidrel, Ovitrelle (choriogonadotropin alfa) is a protein pharmaceutical. Choriogonadotropin alfa was first approved as Ovidrel on 2000-09-20. It is used to treat cryptorchidism, female infertility, and hypogonadism in the USA. It has been approved in Europe to treat anovulation, assisted reproductive techniques, and female infertility.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Ovidrel (discontinued: Ovidrel)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Choriogonadotropin alfa
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Ovidrel | choriogonadotropin alfa | EMD Serono | N-21149 RX | 2003-07-14 | 1 products |
Show 1 discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| female infertility | EFO_0008560 | D007247 | N97 |
| hypogonadism | — | D007006 | E23.0 |
| cryptorchidism | EFO_0004562 | D003456 | Q53.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
394 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | — | — | 2 | 2 | 1 | 1 | 5 |
| Hypogonadism | D007006 | — | E23.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovulation induction | D010062 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Choriogonadotropin alfa |
| INN | choriogonadotropin alfa |
| Description | Choriogonadotropin beta chain [Precursor]; Glycoprotein hormones alpha chain [Precursor]; |
| Classification | Protein |
| Drug class | tricyclic compounds; atropine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | 4986 |
| ChEMBL ID | CHEMBL1201464 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09126 |
| UNII ID | 20ED16GHEB (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,958 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,022 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use